HK1254957A1 - 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途 - Google Patents

作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途 Download PDF

Info

Publication number
HK1254957A1
HK1254957A1 HK18114062.4A HK18114062A HK1254957A1 HK 1254957 A1 HK1254957 A1 HK 1254957A1 HK 18114062 A HK18114062 A HK 18114062A HK 1254957 A1 HK1254957 A1 HK 1254957A1
Authority
HK
Hong Kong
Prior art keywords
efficient
carbon
leaving groups
hydroxamic acids
substituted hydroxamic
Prior art date
Application number
HK18114062.4A
Other languages
English (en)
Chinese (zh)
Inventor
J‧P‧托斯卡诺
J‧P‧托斯卡諾
S‧诺里安
S‧諾里安
Original Assignee
约翰斯霍普金斯大学
約翰斯霍普金斯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 约翰斯霍普金斯大学, 約翰斯霍普金斯大學 filed Critical 约翰斯霍普金斯大学
Publication of HK1254957A1 publication Critical patent/HK1254957A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/50—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18114062.4A 2015-06-26 2016-06-25 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途 HK1254957A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185310P 2015-06-26 2015-06-26
US62/185,310 2015-06-26
PCT/US2016/039453 WO2016210392A1 (en) 2015-06-26 2016-06-25 N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof

Publications (1)

Publication Number Publication Date
HK1254957A1 true HK1254957A1 (zh) 2019-08-02

Family

ID=56409199

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114062.4A HK1254957A1 (zh) 2015-06-26 2016-06-25 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途

Country Status (7)

Country Link
US (1) US10583141B2 (enExample)
EP (1) EP3313831B1 (enExample)
JP (1) JP6820015B2 (enExample)
CN (1) CN107922371B (enExample)
ES (1) ES2871079T3 (enExample)
HK (1) HK1254957A1 (enExample)
WO (1) WO2016210392A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6889704B2 (ja) 2015-10-19 2021-06-18 カルディオキシル ファーマシューティカルズ，インク． ニトロキシルドナーとしてのピラゾロン誘導体
EP3365325A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
KR20190070912A (ko) 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029309T2 (en) * 2006-03-17 2017-02-28 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors
WO2011071951A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
JP5832447B2 (ja) 2009-12-07 2015-12-16 ザ ジョンズ ホプキンス ユニバーシティ ビスアシル化ヒドロキシルアミン誘導体
CA2852914C (en) * 2011-10-17 2019-11-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
ES2749682T3 (es) * 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
EP3148983A1 (en) * 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors

Also Published As

Publication number Publication date
JP6820015B2 (ja) 2021-01-27
JP2018520145A (ja) 2018-07-26
CN107922371B (zh) 2022-04-19
US10583141B2 (en) 2020-03-10
EP3313831B1 (en) 2021-03-10
EP3313831A1 (en) 2018-05-02
ES2871079T3 (es) 2021-10-28
US20180185367A1 (en) 2018-07-05
CN107922371A (zh) 2018-04-17
WO2016210392A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
EP3507367A4 (en) CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
EP3234200A4 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
EP4410805A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
EP3292116B8 (en) 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
HK1216859A1 (zh) Irak抑制劑和其用途
WO2018006074A3 (en) Compounds and methods for modulating rna function
EP3313989A4 (en) Modified crispr rna and modified single crispr rna and uses thereof
EP4524255A3 (en) Methods and compositions for nucleic acid analysis
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
EP4112611A3 (en) Modulators of sestrin-gator2 interaction and uses thereof
MX382276B (es) Recubrimientos acuosos de fijado rápido.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
WO2015077657A3 (en) Stat3 inhibitors and uses thereof
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP4218736A3 (en) Compositions comprising 15-hepe
EP3393525A4 (en) METHODS AND COMPOSITIONS FOR ASSEMBLING NUCLEIC ACIDS
EP3256592A4 (en) Compositions and methods for modulating rna
EP3313393A4 (en) PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF